Lymphoma Hub
Avsnitt

EHA 2026 | What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in CLL?

Lymphoma Hub
Dela

During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in chronic lymphocytic leukemia (CLL)?


This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence

Hosted on Acast. See acast.com/privacy for more information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Scientific Education Support. Innehållet i podden är skapat av Scientific Education Support och inte av, eller tillsammans med, Poddtoppen.